Universidad Peruana Cayetano Heredia

The Tuberculosis Unit (UTB) was founded on 2004.  It was stablished as a space where IMT AvH workers that were currently working on tuberculosis research could assemble and collaborate on their activities.

Since its beginnings, UTB has managed to successfully develop research on epidemiology, diagnostic and treatment on tuberculosis. UTB has participated on several researches of international relevance as an example of this, studies on GeneXpert, MTB/RIF took place in the unit.  On the other hand research on basic science, immunology and cost effectiveness have also taken place on the UTB.

UTB has gather a multidisciplinary team that has achieved to build good relationships with institutions on local, national and international level to work together against tuberculosis.

Research interest

• Diagnostic Methods
• Clinical Trials
• Operational Research
• Qualitative Research
• Systematic reviews / meta-analysis
• Immunology
• Molecular Epidemiology

Organization

Group Coordinator:

  Carlos Seas, MD

 Research team:

• Eduardo Gotuzzo, MD
• Jessica Ricaldi, MD, Ph.D.
• Carlos Zamudio, MD.
• Larissa Otero, MD, MPH
• César Ugarte, MD, MsC
• Juan Agapito, MSc.
• Lic. Tatiana Cáceres
• Francesca Capanni,  MD
• Mateo Prochazka, MD
• Jimena Collantes.
• Juana Sedamano, MD
• Francesca Barletta
• Lena Shah

Colaboration and Fundings

• DISA Lima Este
• Estrategia Nacional de Prevención y Control de Tuberculosis
• Hospital Nacional Cayetano Heredia
• Hospital San Juan de Lurigancho
• Instituto Nacional de Salud
• Dirección General de Epidemiologia
• Pontificia Universidad Católica del Perú
• Universidad Mayor Nacional de San Marcos
• Institute of Tropical Medicine in Antwerp, Béligca
• McGill University, Canada
• Vanderbilt University, EEUU
• University of Alabama at Birmingham, EEUU
• Johns Hopkins University, EEUU
• University of Washington at Seattle, EEUU
• London School of Hygiene and Tropical Medicine, UK
• Imperial College London, UK
• University of Southamptom, UK
• University of Melbourne, Australia
• The Royal Children’s Hospital Melbourne, Australia
• Murdoch Children’s Research Institute, Australia
• Foundation for Innovative New Diagnostics (FIND), Suiza
• Centers for Disease Control and Prevention – TBTrial Consortium, EEUU
• Tibotec Pharmaceutical
• National Institute of Health, EEUU
• Directorate General for Development Cooperation - Belgian Cooperation

Recent Projects

• Matrix Metalloproteinases Degradation Products And Their Correlation With TB , TB / Diabetes Mellitus And TB / HIV
• Cohort Study:  Patients with Pulmonary Tuberculosis.
• Improving the diagnosis of childhood tuberculosis; Validation of new biomarkers in an environment of high prevalence.
• Prospective, Randomized, Blinded Phase 2 Pharmacokinetic/Pharmacodynamic Study of the Efficacy and Tolerability of Levofloxacin in Combination with Optimized Background Regimen (OBR) for the treatment of MDR-TB
• Active search of household contacts of TB cases in high-risk area in Lima, Peru.
• Multicenter study.  Crossectional to determine the ability to improve the diagnosis of TB in a multiplex serology test at the point of care study.
• Evaluation of a Treatment Scheme Rifapentine for the intensive phase of treatment of pulmonary tuberculosis.
• major depressive disorder as a risk factor for Successful changes in the outcome of TB treatment.
• Study of Contacts Residential TB.
• Research household contacts of children under five years of BK positive TB patients in Lima, Peru.

Relevant Publications

• Shah L, Choi HW, Berrang-Ford L, Henostroza G, Krapp F, Zamudio C, Heymann SJ, Kaufman JS, Ciampi A, Seas C, Gotuzzo E, Brewer TF. Geographic predictors of primary multidrug-resistant tuberculosis cases in an endemic area of Lima, Peru. Int J Tuberc Lung Dis. 2014;18(11):1307-14. PMID: 25299862.

• Riza AL, Pearson F, Ugarte-Gil C, Alisjahbana B, van de Vijver S, Panduru NM, Hill PC, Ruslami R, Moore D, Aarnoutse R, Critchley JA, van Crevel R. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol. 2014;2(9):740-53. PMID: 25194887.

• Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De aepe E, van Heeswijk RP, Dannemann B; TMC207-C208 Study Group. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014 21;371(8):723-32. PMID: 25140958.

• Barletta F, Otero L, Collantes J, Asto B, de Jong BC, Seas C, Rigouts L. Genetic variability of Mycobacterium tuberculosis complex in patients with no known risk factors for MDR-TB in the North-Eastern part of Lima, Peru. BMC Infect Dis. 2013;13:397. PubMed PMID: 23984854; PubMed Central PMCID: PMC3765759. 

• Ugarte-Gil C, Ruiz P, Zamudio C, Canaza L, Otero L, Kruger H, Seas C. Association of major depressive episode with negative outcomes of tuberculosis treatment. PLoS One. 2013;8(7):e69514 PubMed PMID: 23922728; PubMed Central PMCID: PMC3726639.

• Ugarte-Gil CA, Elkington P, Gilman RH, Coronel J, Tezera LB, Bernabe-Ortiz A, Gotuzzo E, Friedland JS, Moore DA. Induced sputum MMP-1, -3 & -8 concentrations during treatment of tuberculosis. PLoS One. 2013;8(4):e61333. PubMed PMID: 23613834; PubMed Central PMCID: PMC3632571.

• Carriquiry G, Otero L, González E, Zamudio C, Sánchez E, Nabeta P, Campos M, Echevarría J,Seas C, Gotuzzo E. A diagnostic accuracy study of Xpert®MTB/RIF in HIV-positive patients with high clinical suspicion of pulmonary tuberculosis in Lima, Peru. PLoS One 2012;7(9):e44626. Pubmed PMID: 22970271; PubMed Central PMCID: PMC3436871

• Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, Gler MT, Blakemore R, Worodria W, Gray C, Huang L, Caceres T, Mehdiyev R, Raymond L, Whitelaw A, Sagadevan K, Alexander H, Albert H, Cobelens F, Cox H, Alland D, Perkins MD. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet. 2011;377(9776):1495-505. PubMed PMID: 21507477; PubMed Central PMCID: PMC3085933.

• Otero L, Van Deun A, Agapito J, Ugaz R, Prellwitz G, Gotuzzo E, Van der Stuyft P. Quality assessment of smear microscopy by stratified lot sampling of treatment follow-up slides. Int J Tuberc Lung Dis. 2011;15(2):211-6, i. PubMed PMID:21219683.

• Otero L, Krapp F, Tomatis C, Zamudio C, Matthys F, Gotuzzo E, Van der Stuyft P, Seas C. High prevalence of primary multidrug resistant tuberculosis in personswith no known risk factors. PLoS One. 2011;6(10):e26276. PubMed PMID: 22046266; PubMedCentral PMCID: PMC3203110.

• Brewer TF, Choi HW, Seas C, Krapp F, Zamudio C, Shah L, Ciampi A, Heymann SJ, Gotuzzo E. Self-reported risks for multiple-drug resistance among new tuberculosis cases: implications for drug susceptibility screening and treatment. PLoS One. 2011;6(10):e25861. PubMed PMID: 22022459; PubMed Central PMCID: PMC3194818.

• Gotuzzo E. Xpert MTB/RIF for diagnosis of pulmonary tuberculosis. Lancet Infect Dis. 2011;11(11):802-3. PubMed PMID: 21764385.

• Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010;363(11):1005-15. PubMed PMID:20825313; PubMed Central PMCID: PMC2947799.

Services

TBC rapid diagnostic Methods:                                        GeneXpertTM MTB/Rif (GX) Mycobacteria Growth Indicator Tube (MGIT) TBC Cultures: Löwenstein–Jensen

Contact Info

Address: IMTAvH, 1er piso

Hospital Nacional Cayetano Heredia

Av. Honorio Delgado 262

Urb. Ingeniería, San Martin de Porres. Lima - Perú.

Phone:

• 51-1- 613-9797 anexo 4033
• 51-1-791-2471
• 51-1- 628-2517

E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.